Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma
Andrea Boutros(The University of Sydney), Paola Queirolo, Luca Arecco(Ospedale Policlinico San Martino), Elena Croce(Ospedale Policlinico San Martino), Francesco Spagnolo(Martin University), Riccardo Gili(Ospedale Policlinico San Martino), Federica Cecchi(Ospedale Policlinico San Martino), Enrica T. Tanda(Ospedale Policlinico San Martino)
Cited by 39
Related Papers
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2017|491
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
|The Lancet Oncology|2021|389
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility
|Nature Genetics|2020|238
The treatment of advanced melanoma: Current approaches and new challenges
|Critical Reviews in Oncology/Hematology|2024|140
Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy
|Seminars in Cancer Biology|2019|119